002603 以岭药业
已收盘 09-03 15:00:00
资讯
新帖
简况
双奖加冕！以岭药业斩获”第七届全景投资者关系金奖“两项荣誉
证券之星 · 09-02 18:22
双奖加冕！以岭药业斩获”第七届全景投资者关系金奖“两项荣誉
以岭药业：8月29日召开业绩说明会，华创证券、国盛证券等多家机构参与
证券之星 · 08-31
以岭药业：8月29日召开业绩说明会，华创证券、国盛证券等多家机构参与
股市必读：以岭药业新发布《2026年半年度报告摘要》
证券之星 · 08-31
股市必读：以岭药业新发布《2026年半年度报告摘要》
以岭药业2026上半年营收超40亿元，净利润7.57亿元
证券之星 · 08-28
以岭药业2026上半年营收超40亿元，净利润7.57亿元
股市必读：以岭药业新发布《关于全资孙公司收到化学原料药欧洲CEP证书的公告》
证券之星 · 08-28
股市必读：以岭药业新发布《关于全资孙公司收到化学原料药欧洲CEP证书的公告》
以岭药业最新公告：全资孙公司获来曲唑原料药欧洲CEP证书
证券之星 · 08-26
以岭药业最新公告：全资孙公司获来曲唑原料药欧洲CEP证书
8月20日以岭药业涨5.27%，中药ETF汇添富基金重仓该股
证券之星 · 08-20
8月20日以岭药业涨5.27%，中药ETF汇添富基金重仓该股
抗衰老产业持续受到关注：八子补肾入选《中国抗衰老产业年度报告》，以岭药业核心价值凸显
证券之星 · 08-17
抗衰老产业持续受到关注：八子补肾入选《中国抗衰老产业年度报告》，以岭药业核心价值凸显
股市必读：以岭药业新发布《关于化药创新药LB220-D08缓释片药物临床试验申请获得受理的公告》
证券之星 · 08-14
股市必读：以岭药业新发布《关于化药创新药LB220-D08缓释片药物临床试验申请获得受理的公告》
以岭药业(002603.SZ)：化药创新药“LB220-D08缓释片”药物临床试验申请获得受理
智通财经 · 08-12
以岭药业(002603.SZ)：化药创新药“LB220-D08缓释片”药物临床试验申请获得受理
以岭药业：未来将更加重视现金分红
证券之星 · 08-05
以岭药业：未来将更加重视现金分红
以岭药业：7月21日高管赵韶华增持股份合计100股
证券之星 · 07-22
以岭药业：7月21日高管赵韶华增持股份合计100股
7月20日以岭药业涨6.67%，长信金利趋势混合A基金重仓该股
证券之星 · 07-20
7月20日以岭药业涨6.67%，长信金利趋势混合A基金重仓该股
以岭药业茂丰绿科驴肉被纳入全国特质农品名录 国字号品质认证再添硕果
证券之星 · 07-13
以岭药业茂丰绿科驴肉被纳入全国特质农品名录 国字号品质认证再添硕果
“国字号”认证！以岭药业茂丰鸡蛋入选全国特质农品名录
证券之星 · 07-13
“国字号”认证！以岭药业茂丰鸡蛋入选全国特质农品名录
7月13日以岭药业涨6.19%，长信金利趋势混合A基金重仓该股
证券之星 · 07-13
7月13日以岭药业涨6.19%，长信金利趋势混合A基金重仓该股
以岭药业获评“2025星岛环球中国・杰出领袖出海企业”
证券之星 · 07-10
以岭药业获评“2025星岛环球中国・杰出领袖出海企业”
以岭药业（002603）披露公司及全资子公司7个专利产品进入《国家基本药物目录》（2026年版），7月9日股价下跌1.24%
证券之星 · 07-09
以岭药业（002603）披露公司及全资子公司7个专利产品进入《国家基本药物目录》（2026年版），7月9日股价下跌1.24%
以岭药业最新公告：全资孙公司获厄贝沙坦原料药上市批准
证券之星 · 07-06
以岭药业最新公告：全资孙公司获厄贝沙坦原料药上市批准
以岭药业：联动传统媒体、新媒体、户外媒体如各大高铁站大屏等多形式、多场景、多频次内容投放
证券之星 · 07-03
以岭药业：联动传统媒体、新媒体、户外媒体如各大高铁站大屏等多形式、多场景、多频次内容投放
加载更多
公司概况
公司名称：
石家庄以岭药业股份有限公司
所属行业：
医药制造业
上市日期：
2011-07-28
主营业务：
石家庄以岭药业股份有限公司的主营业务是专利创新中药的研发、生产和销售。公司的主要产品是专利中药产品。公司获得了国家科技进步一等奖1项、国家科技进步二等奖4项、国家技术发明二等奖1项及省部级科技奖励20余项。
发行价格：
34.56
{"stockData":{"symbol":"002603","market":"SZ","secType":"STK","nameCN":"以岭药业","latestPrice":15.72,"timestamp":1788419004000,"preClose":15.75,"halted":0,"volume":10305596,"delay":0,"changeRate":-0.0019,"floatShares":1376000000,"shares":1671000000,"eps":0.8232,"marketStatus":"已收盘","change":-0.03,"latestTime":"09-03 15:00:00","open":15.72,"high":15.83,"low":15.6,"amount":162000000,"amplitude":0.0146,"askPrice":15.73,"askSize":92,"bidPrice":15.72,"bidSize":270,"shortable":0,"etf":0,"ttmEps":0.8232,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1788485400000},"marketStatusCode":5,"adr":0,"adjPreClose":15.75,"symbolType":"stock","openAndCloseTimeList":[[1788399000000,1788406200000],[1788411600000,1788418800000]],"highLimit":17.33,"lowLimit":14.18,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1670705376,"isCdr":false,"pbRate":2.41,"roa":"--","peRate":19.09621,"roe":"6.66%","epsLYR":0.77,"committee":-0.531243,"marketValue":26263000000,"turnoverRate":0.0075,"status":1,"floatMarketCap":21635000000},"requestUrl":"/m/hq/s/002603","defaultTab":"news","newsList":[{"id":"2664813198","title":"双奖加冕！以岭药业斩获”第七届全景投资者关系金奖“两项荣誉","url":"https://stock-news.laohu8.com/highlight/detail?id=2664813198","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664813198?lang=zh_cn&edition=full","pubTime":"2026-09-02 18:22","pubTimestamp":1788344565,"startTime":"0","endTime":"0","summary":"8月28日，“中国上市公司投资者关系年度盛典”在雄安新区隆重举行，现场正式揭晓了“第七届全景投资者关系金奖”获奖名单。自上市以来，以岭药业始终坚持“真实、准确、完整”的信息披露原则，持续深耕信息披露与投资者关系工作。吴瑞作为以岭药业的董事会秘书，在公司治理、信息发布、投资者关系管理等方面表现突出，获得了评审团和资本市场的高度认可。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/SS2026090200035097.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0239","BK0042","BK0097","002603","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663052870","title":"以岭药业：8月29日召开业绩说明会，华创证券、国盛证券等多家机构参与","url":"https://stock-news.laohu8.com/highlight/detail?id=2663052870","media":"证券之星","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663052870?lang=zh_cn&edition=full","pubTime":"2026-08-31 21:04","pubTimestamp":1788181469,"startTime":"0","endTime":"0","summary":"证券之星消息，2026年8月31日以岭药业发布公告称公司于2026年8月29日召开业绩说明会，华创证券、国盛证券、长城证券、华源证券、华安证券、中邮证券、长江证券、国金证券、投资机构、国联民生证券、中信建投证券、中金公司、国投证券、开源证券、兴业证券、国泰海通证券、华泰证券参与。今年，苯胺洛芬注射液已获批上市，已进入商业化阶段。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026083100034829.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0097","BK0188","161027","BK0276","002670","BK0239","BK0046","BK0052","002603","BK0042"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663504783","title":"股市必读：以岭药业新发布《2026年半年度报告摘要》","url":"https://stock-news.laohu8.com/highlight/detail?id=2663504783","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663504783?lang=zh_cn&edition=full","pubTime":"2026-08-31 04:03","pubTimestamp":1788120193,"startTime":"0","endTime":"0","summary":"截至2026年8月28日收盘，以岭药业报收于16.18元，下跌0.43%，换手率0.93%，成交量12.81万手，成交额2.07亿元。股本股东变化股东户数变动截至2026年6月30日公司股东户数为14.0万户，较3月31日减少7962.0户，减幅为5.38%；户均持股数量由上期的1.13万股增加至1.19万股，户均持股市值为17.9万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026083100001105.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0097","BK0046","BK0042","BK0239","BK0188","002603"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662006439","title":"以岭药业2026上半年营收超40亿元，净利润7.57亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2662006439","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662006439?lang=zh_cn&edition=full","pubTime":"2026-08-28 18:33","pubTimestamp":1787913221,"startTime":"0","endTime":"0","summary":"8月28日晚间，以岭药业披露2026年半年报显示，公司上半年实现营业收入40.75亿元，同比增长0.86%；归属于上市公司股东的净利润达7.57亿元，同比增长13.28%；经营活动产生的现金流量净额为11.80亿元，同比增长41.79%。以岭药业2026年半年报显示，公司持续的高研发投入开发更多创新产品，产品管线丰富优势显著，在提高经营收入的同时，利润和现金流持续改善，验证了公司高质量发展。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/SS2026082800043604.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002603"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662750037","title":"股市必读：以岭药业新发布《关于全资孙公司收到化学原料药欧洲CEP证书的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2662750037","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662750037?lang=zh_cn&edition=full","pubTime":"2026-08-28 09:29","pubTimestamp":1787880593,"startTime":"0","endTime":"0","summary":"公司公告汇总关于全资孙公司收到化学原料药欧洲CEP证书的公告石家庄以岭药业股份有限公司全资孙公司万洋衡水制药有限公司收到欧洲药品质量管理局签发的来曲唑原料药欧洲药典适用性证书，证书编号CEP-2026-058-Rev 00。来曲唑是一种非甾体类芳香化酶抑制剂，用于绝经后激素受体阳性乳腺癌的辅助治疗及晚期乳腺癌治疗。获得CEP证书表明该原料药质量获欧洲规范市场认可，具备进入欧盟及承认CEP证书其他市场的资质。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082800017019.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0097","BK0239","002603","BK0046","BK0188","BK0042"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662914667","title":"以岭药业最新公告：全资孙公司获来曲唑原料药欧洲CEP证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2662914667","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662914667?lang=zh_cn&edition=full","pubTime":"2026-08-26 17:18","pubTimestamp":1787735939,"startTime":"0","endTime":"0","summary":"以岭药业(002603.SZ)公告称，公司全资孙公司万洋衡水制药有限公司收到欧洲药品质量管理局签发的来曲唑原料药欧洲药典适用性证书。该证书表明来曲唑原料药获欧盟市场准入资质，有助于公司拓展国际市场，但药品生产销售存在不确定性，投资者需注意风险。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082600038202.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0042","BK0046","BK0097","BK0239","BK0188","002603"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660240225","title":"8月20日以岭药业涨5.27%，中药ETF汇添富基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2660240225","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660240225?lang=zh_cn&edition=full","pubTime":"2026-08-20 16:40","pubTimestamp":1787215249,"startTime":"0","endTime":"0","summary":"证券之星消息，8月20日以岭药业涨5.27%，收盘报17.38元，换手率4.07%，成交量56.05万手，成交额9.67亿元。根据2026基金半年报公募基金重仓股数据，重仓该股的公募基金共6家，其中持有数量最多的公募基金为汇添富基金的中药ETF汇添富。中药ETF汇添富目前规模为23.05亿元，最新净值0.9738，较上一交易日下跌0.99%，近一年下跌14.74%。中药ETF汇添富的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082000028950.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0042","BK0046","BK0239","002603","560080","BK0188","BK0097"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660610596","title":"抗衰老产业持续受到关注：八子补肾入选《中国抗衰老产业年度报告》，以岭药业核心价值凸显","url":"https://stock-news.laohu8.com/highlight/detail?id=2660610596","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660610596?lang=zh_cn&edition=full","pubTime":"2026-08-17 08:30","pubTimestamp":1786926625,"startTime":"0","endTime":"0","summary":"2026年8月15日，由中国民族卫生协会、浙江清华长三角研究院、中国民族卫生协会抗衰老专业委员会共同编写的《中国抗衰老产业年度报告》正式发布。以岭药业八子补肾胶囊相关研究被报告收录，也使中医药抗衰老的证据建设与产业转化再次受到关注。结语八子补肾胶囊被《中国抗衰老产业年度报告》收录，是以岭药业持续深耕抗衰老领域、推进创新研发的一个缩影。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/SS2026081700001688.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0239","BK0042","BK0097","002603","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659694181","title":"股市必读：以岭药业新发布《关于化药创新药LB220-D08缓释片药物临床试验申请获得受理的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2659694181","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659694181?lang=zh_cn&edition=full","pubTime":"2026-08-14 01:20","pubTimestamp":1786641659,"startTime":"0","endTime":"0","summary":"截至2026年8月13日收盘，以岭药业报收于17.1元，上涨1.91%，换手率3.09%，成交量42.57万手，成交额7.3亿元。当日关注点交易信息汇总：8月13日主力资金净流入1157.6万元，占总成交额1.59%。公司公告汇总：以岭药业自主研发的1类化学新药LB220-D08缓释片临床试验申请获国家药监局受理。该药为靶向Factor B因子的补体抑制剂，可选择性抑制补体旁路途径，抑制毒素生成及膜攻击复合物形成，同时保留凝集素和经典途径功能。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081400000866.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002603","BK0042","159992","BK1161","BK0097","BK0188","BK1574","06978","BK0046","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658978437","title":"以岭药业(002603.SZ)：化药创新药“LB220-D08缓释片”药物临床试验申请获得受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2658978437","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658978437?lang=zh_cn&edition=full","pubTime":"2026-08-12 17:00","pubTimestamp":1786525244,"startTime":"0","endTime":"0","summary":"智通财经APP讯，以岭药业(002603.SZ)发布公告，近日，公司收到国家药品监督管理局核准签发的《受理通知书》，该药物名称：“LB220-D08缓释片”。LB220-D08为公司自主研发的全新小分子化学药物，是公司具有独立知识产权的1类化学新药。本品为靶向FactorB因子的补体抑制剂。通过靶向抑制B因子，本品可选择性抑制旁路途径，阻止C3转化酶的活化，从而抑制C3a、C5a等毒素的生成以及C5转化酶和膜攻击复合物(MAC，C5b-9)的形成，并保持凝集素和经典途径信号通路的正常功能。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1478999.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["MEDX","BK0046","MDTX","BK0042","BK0097","BK0188","BK1574","159992","LNGR","PSYK","002603","BK0239","IBBQ","BMED","06978","IBBJ","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657512105","title":"以岭药业：未来将更加重视现金分红","url":"https://stock-news.laohu8.com/highlight/detail?id=2657512105","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657512105?lang=zh_cn&edition=full","pubTime":"2026-08-05 17:00","pubTimestamp":1785920450,"startTime":"0","endTime":"0","summary":"证券之星消息，以岭药业08月05日在投资者关系平台上答复投资者关心的问题。公司未来，也将根据实际经营业绩情况，在符合公司利润分配政策、保障公司正常运营和长远发展的前提下，会更加重视现金分红，更好地回报广大股东。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080500030872.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0042","BK0046","BK0097","BK0188","002603","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653768770","title":"以岭药业：7月21日高管赵韶华增持股份合计100股","url":"https://stock-news.laohu8.com/highlight/detail?id=2653768770","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653768770?lang=zh_cn&edition=full","pubTime":"2026-07-22 21:01","pubTimestamp":1784725305,"startTime":"0","endTime":"0","summary":"证券之星消息，根据7月22日市场公开信息、上市公司公告及交易所披露数据整理，以岭药业最新董监高及相关人员股份变动情况：2026年7月21日公司高管赵韶华共增持公司股份100.0股，占公司总股本为0.0001%。以岭药业近半年内的董监高及核心技术人员增减持详情如下：以岭药业的高管列表及最新持股情况如下：融资融券数据显示该股近5日融资净流入1051.63万，融资余额增加；融券净流出25.02万，融券余额减少。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072200045517.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0042","BK0097","BK0188","002603","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652296123","title":"7月20日以岭药业涨6.67%，长信金利趋势混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2652296123","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2652296123?lang=zh_cn&edition=full","pubTime":"2026-07-20 16:41","pubTimestamp":1784536886,"startTime":"0","endTime":"0","summary":"证券之星消息，7月20日以岭药业涨6.67%，收盘报17.6元，换手率4.69%，成交量64.59万手，成交额11.09亿元。根据2026基金Q1季报公募基金重仓股数据，重仓该股的公募基金共8家，其中持有数量最多的公募基金为长信基金的长信金利趋势混合A。长信金利趋势混合A目前规模为35.61亿元，最新净值0.3943，较上一交易日下跌0.15%，近一年上涨27.87%。长信金利趋势混合A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072000024960.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0097","BK0046","BK0042","BK0239","BK0188","002603"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651719796","title":"以岭药业茂丰绿科驴肉被纳入全国特质农品名录 国字号品质认证再添硕果","url":"https://stock-news.laohu8.com/highlight/detail?id=2651719796","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651719796?lang=zh_cn&edition=full","pubTime":"2026-07-13 17:13","pubTimestamp":1783933997,"startTime":"0","endTime":"0","summary":"近日，经农业农村部农产品质量安全中心多轮严格评审，以岭药业全资子公司故城县茂丰农业科技开发有限公司旗下的茂丰绿科驴肉被纳入全国特质农品名录，获评国家级特质农品称号。特质农品的入选门槛堪称严苛，需要经过全维度层层闯关考核。本次获选，标志着茂丰公司在特色农业领域的品质实力获得国家级权威认可。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/SS2026071300024987.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0097","BK0239","002603","BK0046","BK0188","BK0042"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651936197","title":"“国字号”认证！以岭药业茂丰鸡蛋入选全国特质农品名录","url":"https://stock-news.laohu8.com/highlight/detail?id=2651936197","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651936197?lang=zh_cn&edition=full","pubTime":"2026-07-13 17:12","pubTimestamp":1783933945,"startTime":"0","endTime":"0","summary":"近日，经农业农村部农产品质量安全中心多轮严格评审，以岭药业全资子公司故城县茂丰农业科技开发有限公司旗下的茂丰鸡蛋成功登录全国特质农品名录，获颁国家级特质农品证书。本次茂丰鸡蛋被纳入全国特质农品名录，不仅是官方和行业对茂丰鸡蛋独特风味、稳定品质的充分肯定，更成为茂丰公司特色种养殖产业品质升级的标志性成果。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/SS2026071300024943.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002603","BK0046","BK0188","BK0097","BK0239","BK0042"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651606192","title":"7月13日以岭药业涨6.19%，长信金利趋势混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2651606192","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651606192?lang=zh_cn&edition=full","pubTime":"2026-07-13 16:46","pubTimestamp":1783932371,"startTime":"0","endTime":"0","summary":"证券之星消息，7月13日以岭药业涨6.19%，收盘报16.47元，换手率4.17%，成交量57.45万手，成交额9.47亿元。根据2026基金Q1季报公募基金重仓股数据，重仓该股的公募基金共8家，其中持有数量最多的公募基金为长信基金的长信金利趋势混合A。长信金利趋势混合A目前规模为35.61亿元，最新净值0.3943，较上一交易日下跌0.15%，近一年上涨27.87%。长信金利趋势混合A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071300023687.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002603","BK0042","BK0046","BK0188","BK0097","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650885891","title":"以岭药业获评“2025星岛环球中国・杰出领袖出海企业”","url":"https://stock-news.laohu8.com/highlight/detail?id=2650885891","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2650885891?lang=zh_cn&edition=full","pubTime":"2026-07-10 15:44","pubTimestamp":1783669463,"startTime":"0","endTime":"0","summary":"7月9日，星岛新闻集团“2025杰出领袖选举”颁奖晚宴在深圳、香港两地同步举办。以岭药业凭借在中医药现代化与国际化领域的突出贡献，荣获“2025星岛环球中国杰出领袖出海企业”奖项。作为获奖企业代表，以岭药业在国际化进程中走出了一条独特路径。据悉，“2025星岛环球中国·杰出领袖出海企业”奖项由星岛新闻集团首次发起设立，旨在表彰在中国企业全球化进程中取得卓越成就的行业标杆。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/SS2026071000024428.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK1130","01105","BK0042","BK0097","BK0046","002603","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650204049","title":"以岭药业（002603）披露公司及全资子公司7个专利产品进入《国家基本药物目录》（2026年版），7月9日股价下跌1.24%","url":"https://stock-news.laohu8.com/highlight/detail?id=2650204049","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2650204049?lang=zh_cn&edition=full","pubTime":"2026-07-09 22:19","pubTimestamp":1783606755,"startTime":"0","endTime":"0","summary":"截至2026年7月9日收盘，以岭药业报收于15.19元，较前一交易日下跌1.24%，最新总市值为253.78亿元。近日，以岭药业披露《关于公司及全资子公司专利产品进入〈国家基本药物目录〉的公告》。公告显示，国家卫生健康委员会于2026年7月9日发布《国家基本药物目录》，自2026年9月1日起施行。上述产品均为公司独家专利中药，2025年合计收入606,920.11万元，占公司主营业务收入的77.50%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070900042429.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002603","BK0046","BK0188","BK0042","BK0097"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649640960","title":"以岭药业最新公告：全资孙公司获厄贝沙坦原料药上市批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2649640960","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2649640960?lang=zh_cn&edition=full","pubTime":"2026-07-06 17:32","pubTimestamp":1783330334,"startTime":"0","endTime":"0","summary":"以岭药业(002603.SZ)公告称，公司全资孙公司万洋衡水制药有限公司收到国家药监局下发的《化学原料药上市申请批准通知书》，其提交的“厄贝沙坦”原料药上市申请获批。该药品用于原发性高血压及合并高血压的2型糖尿病肾病治疗，将丰富公司产品线，但短期内不会对当期业绩产生重大影响。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070600024204.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0239","BK0042","BK0097","002603","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648261634","title":"以岭药业：联动传统媒体、新媒体、户外媒体如各大高铁站大屏等多形式、多场景、多频次内容投放","url":"https://stock-news.laohu8.com/highlight/detail?id=2648261634","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2648261634?lang=zh_cn&edition=full","pubTime":"2026-07-03 09:06","pubTimestamp":1783040766,"startTime":"0","endTime":"0","summary":"投资者提问：请问董秘，有看到网络消息，公司在2026年春节期间在高铁站有大量广告推广，是否属实，如果有是在哪些地方有增加广告，我在南京，上海，杭州等地都没有看到以岭药业回复：投资者您好，公司积极加强企业品牌和产品品牌建设，联动传统媒体、新媒体、户外媒体如各大高铁站大屏等多形式、多场景、多频次内容投放，全面提升企业品牌形象与产品知名度，强化用户品牌记忆，从而助力产品终端销售转化。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070300009492.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0042","BK0239","BK0046","BK0097","002603","BK0188"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1788462447991,"stockEarnings":[{"period":"1week","weight":-0.0326},{"period":"1month","weight":-0.0637},{"period":"3month","weight":0.0538},{"period":"6month","weight":-0.0317},{"period":"1year","weight":-0.0028},{"period":"ytd","weight":-0.0492}],"compareEarnings":[{"period":"1week","weight":-0.0037},{"period":"1month","weight":0.0313},{"period":"3month","weight":-0.0213},{"period":"6month","weight":-0.0442},{"period":"1year","weight":0.0337},{"period":"ytd","weight":-0.0067}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"石家庄以岭药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"140038人(较上一季度减少5.38%)","perCapita":"9827股","listingDate":"2011-07-28","address":"河北省石家庄市裕华区高新技术产业开发区天山大街238号","registeredCapital":"167070万元","survey":" 石家庄以岭药业股份有限公司的主营业务是专利创新中药的研发、生产和销售。公司的主要产品是专利中药产品。公司获得了国家科技进步一等奖1项、国家科技进步二等奖4项、国家技术发明二等奖1项及省部级科技奖励20余项。","listedPrice":34.56},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"以岭药业(002603)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供以岭药业(002603)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"以岭药业,002603,以岭药业股票,以岭药业股票老虎,以岭药业股票老虎国际,以岭药业行情,以岭药业股票行情,以岭药业股价,以岭药业股市,以岭药业股票价格,以岭药业股票交易,以岭药业股票购买,以岭药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"以岭药业(002603)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供以岭药业(002603)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}